Utilize este identificador para referenciar este registo:
https://hdl.handle.net/1822/57888
Título: | Safinamide: a new hope for Parkinson's disease? |
Autor(es): | Teixeira, Fábio Gabriel Rodrigues Gago, Miguel F. Marques, Paulo César Gonçalves Moreira, Pedro Miguel Silva Magalhães, Ricardo José Silva Sousa, Nuno Salgado, A. J. |
Palavras-chave: | Alanine Animals Antiparkinson Agents Benzylamines Humans Levodopa Neuroprotective Agents Parkinson Disease |
Data: | 2018 |
Editora: | Elsevier 1 |
Revista: | Drug Discovery Today |
Resumo(s): | The loss of dopaminergic neurons (DAn) and reduced dopamine (DA) production underlies the reasoning behind the gold standard treatment for Parkinson's disease (PD) using levodopa (L-DOPA). Recently licensed by the European Medicine Agency (EMA) and US Food and Drug Administration (FDA), safinamide [a monoamine oxidase B (MOA-B) inhibitor] is an alternative to L-DOPA; as we discuss here, it enhances dopaminergic transmission with decreased secondary effects compared with L-DOPA. In addition, nondopaminergic actions (neuroprotective effects) have been reported, with safinamide inhibiting glutamate release and sodium/calcium channels, reducing the excitotoxic input to dopaminergic neuronal death. Effects of safinamide have been correlated with the amelioration of non-motor symptoms (NMS), although these remain under discussion. Overall, safinamide can be considered to have potential antidyskinetic and neuroprotective effects and future trials and/or studies should be performed to provide further evidence for its potential as an anti-PD drug. |
Tipo: | Artigo |
URI: | https://hdl.handle.net/1822/57888 |
DOI: | 10.1016/j.drudis.2018.01.033 |
ISSN: | 1359-6446 |
Arbitragem científica: | yes |
Acesso: | Acesso aberto |
Aparece nas coleções: | ICVS - Artigos em revistas internacionais / Papers in international journals |
Ficheiros deste registo:
Ficheiro | Descrição | Tamanho | Formato | |
---|---|---|---|---|
Teixeira FG. Safinamide- a new hope for Parkinson’s disease_.pdf | 1,03 MB | Adobe PDF | Ver/Abrir |